Optimization of trans-Resveratrol bioavailability for human therapy

HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS

Thomas Walle, Faye Hsieh, Mark H. DeLegge et al. · Drug Metabolism and Disposition · 2004 · 1.8K citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis

Victoria Brown, Ketan Patel, Maria Viskaduraki et al. · Cancer Research · 2010 · 683 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients

Ketan Patel, Victoria Brown, Donald J. L. Jones et al. · Cancer Research · 2010 · 613 citations · Full text

Medicine, Oncology, Pharmacology +14

Pharmacokinetic and safety profile of<i>trans</i>‐resveratrol in a rising multiple‐dose study in healthy volunteers

Luís Almeida, Manuel Vaz‐da‐Silva, Amílcar Falcão et al. · Molecular Nutrition & Food Research · 2009 · 426 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Resveratrol Has Antagonist Activity on the Aryl Hydrocarbon Receptor: Implications for Prevention of Dioxin Toxicity

Robert F. Casper, Monique Quesne, Ian M. Rogers et al. · Molecular Pharmacology · 1999 · 416 citations

Pharmacy, Pharmacology, Toxicology +10